Home How It Works Goals Protocols Lab Tests Peptides Blog About Log In Get Started

Peptide Library

TB-500 / Thymosin Beta-4

Thymosin Beta-4 is a naturally occurring, ubiquitously expressed 43-amino acid peptide that regulates actin dynamics — the cellular machinery underlying tissue movement, repair, and regeneration. TB-500 is a synthetic version of its active actin-binding fragment. Preclinical evidence is extensive. Human systemic RCTs do not exist. Topical Tβ4 has reached Phase 2 clinical trials for corneal healing. Evidence level: Level IV–V (predominantly preclinical; Level II for topical corneal applications).

Regulatory alert — read first

TB-500 is prohibited by WADA and under FDA review in July 2026.

⚠ Regulatory Status — Two Critical Facts

WADA prohibition: TB-500 is prohibited by WADA under the Prohibited List classification for "Other Peptide Hormones and Related Substances." Athletes in sanctioned sports face anti-doping violations for TB-500 use. This is distinct from BPC-157, which is not currently on WADA's prohibited list. Competitive athletes must not use TB-500.

FDA PCAC meeting — July 23, 2026: TB-500 / Thymosin Beta-4 is among the peptides under consideration at the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026, for potential addition to the 503A bulk drug substances list. As of May 2026, TB-500 is not on the FDA-approved 503A bulks list and generally cannot be legally compounded under standard 503A frameworks. The July 2026 meeting is a potential inflection point. Outcomes are not predetermined. Any clinical program involving TB-500 should obtain real-time legal and compliance guidance.

Mechanism of action

What TB-500 is and how it works.

Thymosin Beta-4 is one of the most abundant intracellular peptides in mammalian tissue — found at high concentrations in platelets, white blood cells, and virtually every organ system. Its central physiological role is regulation of actin dynamics, the cytoskeletal process underlying cell movement, division, and tissue organization. TB-500 is the synthetic version of its active actin-binding domain (LKKTETQ, amino acids 17–23) — a fragment shown in research to retain the parent molecule's key biological activities.

G-Actin Sequestration

Tβ4 binds to monomeric (globular, "G") actin and sequesters it, modulating the balance between G-actin and polymerized F-actin in the cytoskeleton. This prevents inappropriate actin polymerization and promotes ordered cytoskeletal assembly in migrating cells — essential for directed cell movement during wound repair and tissue regeneration.

Cell Migration Enhancement

By regulating actin dynamics, Tβ4 promotes the migration of keratinocytes, fibroblasts, and endothelial cells — all essential for wound repair and tissue remodeling. In wound healing, coordinated cell migration from the wound margin is a rate-limiting step; Tβ4's enhancement of this process is consistently observed in animal models.

Angiogenesis — VEGF Upregulation

Tβ4 stimulates endothelial cell migration and tube formation, upregulates VEGF, and promotes vascularization of injured tissue. Adequate blood vessel formation is critical for delivering oxygen and nutrients to healing tissue. This pro-angiogenic activity is shared with BPC-157 and carries the same theoretical oncology-related safety consideration.

Anti-Inflammatory Activity

Tβ4 downregulates NF-κB activity and reduces pro-inflammatory cytokine expression — a mechanism that may reduce collateral tissue damage during acute inflammation and support transition to the repair phase. This anti-inflammatory activity has been observed consistently across multiple animal models of injury and disease.

Anti-Fibrotic Effects

Tβ4 may reduce scar formation by modulating matrix metalloproteinase (MMP) activity and influencing fibroblast differentiation toward a less fibrotic phenotype. Anti-fibrotic activity is particularly relevant in cardiac injury models, where excessive fibrosis after myocardial infarction impairs function — an area where Tβ4 has been studied preclinically.

Cardiac and Corneal Repair

Tβ4 has demonstrated cardiomyocyte protection and epicardial progenitor cell activation in cardiac injury animal models. Its corneal healing application (RGN-259 topical drops, RegeneRx) represents the most clinically advanced Tβ4 use — Phase 2 trials have been completed for dry eye and neurotrophic keratitis. Topical corneal use does not validate systemic injection protocols.

What patients explore it for

Clinical interests — with honest evidence context.

Outside of corneal applications (where topical Tβ4 eye drops are in clinical trials), virtually all systemic therapeutic claims for TB-500 in musculoskeletal and soft tissue healing are based on preclinical animal models without completed human RCTs. This context is essential for informed decision-making.

Musculoskeletal Injury Recovery

Muscle tears, tendon injuries, ligament sprains, and chronic overuse injuries — particularly in athletic populations. The mechanism is biologically coherent. All supporting evidence is from animal models. Whether these effects translate to human systemic injection for sports injuries is scientifically unproven.

Post-Surgical Wound Healing

TB-500 is explored for healing acceleration after surgery. Animal wound healing models consistently show accelerated closure, increased collagen deposition, and improved vascularization. Human post-surgical controlled trials do not exist.

Anti-Fibrotic Applications

Reducing scar tissue formation after injury or surgery. The anti-fibrotic mechanisms are preclinically established, particularly in cardiac and dermal models. Clinical application for scar reduction in humans has not been studied in controlled trials.

Corneal Healing — Most Clinically Advanced

Tβ4 eye drops (RGN-259, RegeneRx) have completed Phase 2 clinical trials for dry eye and neurotrophic keratitis. This represents the most human-validated Tβ4 application — but it is a topical formulation for a specific ocular indication, and these results do not validate systemic injection for musculoskeletal use.

Cardiovascular Recovery

Experimental use following cardiac events — based on preclinical data showing Tβ4 reduces cardiomyocyte death and supports vascular repair after myocardial infarction in animal models. Not an established clinical practice; this is a research-stage application with no human cardiac RCT data for Tβ4/TB-500.

Neuroprotection

Emerging preclinical data on Tβ4 in traumatic brain injury models. Among the more speculative clinical interests — mechanistically proposed but unsupported by human clinical data of any type.

Evidence summary

What the research shows — and where it stops.

The evidence base for systemic TB-500 is predominantly preclinical. A 2025 review comparing BPC-157 and TB-500 explicitly described both compounds as representing "a fundamental chasm between pre-clinical data and clinical reality." All PMIDs below are verified against PubMed.

Thymosin Beta-4 — Rat Wound Healing

PMID: 10469335 · Malinda et al., J Invest Dermatol 1999 · Evidence: Level IV (animal)

In a rat full-thickness wound model, topical and intraperitoneal Tβ4 administration increased reepithelialization by 42% at 4 days and 61% at 7 days compared to saline controls, with increased collagen deposition and angiogenesis. Tβ4 stimulated keratinocyte migration 2–3 fold in Boyden chamber assays. Among the earliest and most cited demonstrations of Tβ4's wound-healing activity. Animal data.

Tβ4 in Diabetic and Aged Mice

PMID: 12581423 · Philp et al., Wound Repair Regen 2003 · Evidence: Level IV (animal)

In db/db diabetic mice (where wound healing is severely impaired) and in aged mice (26 months), Tβ4 significantly accelerated wound closure, increased wound contracture, and enhanced collagen deposition. The active actin-binding domain (LKKTETQ — the basis for TB-500) duplicated the parent molecule's effects — supporting the rationale for the shorter synthetic fragment. Preclinical data in diabetic mouse models.

Tβ4 Cardiac and Multi-Tissue Review

DOI: 10.1016/bs.vh.2016.04.005 · Kleinman HK, Sosne G · Evidence: Level V (review)

This influential review summarized Tβ4's pleiotropic activities across dermal healing, corneal healing, cardiac repair, and neuroprotection. The authors note Tβ4 promotes activation of epicardial progenitor cells following myocardial infarction in animal models, reduces cardiomyocyte death, and supports vascular repair. All applications described remain preclinical for cardiac use.

Engineered Tandem Tβ4 — Corneal Healing

DOI: 10.1167/iovs.66.14.31 · Nguyen et al. 2025, IOVS · Evidence: Level IV (animal, topical)

A 2025 study engineered a dimeric form of Tβ4 with enhanced corneal wound-healing activity — reducing scarring with greater efficacy than native Tβ4 in a murine alkali injury model. This represents the frontier of Tβ4 clinical development in corneal applications. This is topical, ocular use research — it does not validate systemic injection for musculoskeletal applications.

BPC-157 & TB-500 Systematic Analysis

DOI: 10.31891/pcs.2025.4.2 · Chornomydz & Klantsa 2025 · Evidence: Level III (systematic review)

This comprehensive 2025 review critically analyzed both compounds from a sports medicine perspective. For TB-500: "TB4 has undergone some clinical trials in other fields (e.g., chronic wound healing), but its efficacy in sports injuries is unproven. Moreover, its ability to stimulate cell migration and angiogenesis carries theoretical oncogenic risks." Conclusion: "The available data confirm that the use of BPC-157 and TB-500 for treating sports injuries in humans is currently a form of unregulated self-experimentation."

Dosing context — educational only

What clinical settings describe — no FDA protocol exists.

⚠ EDUCATIONAL ONLY — Not a Prescription. No FDA-Approved Protocol Exists.

No FDA-approved dosing protocol for systemic TB-500/Thymosin Beta-4 exists. No human dose-finding studies have been conducted for systemic injection. All dosing described in clinical settings is empirically derived — not clinically validated. Any clinician prescribing systemic TB-500 is operating outside FDA-approved parameters. The information below describes what has been reported; it is not a recommendation and should not guide self-administration.

Systemic Injection — Described Clinical Ranges

Typical systemic doses described in clinical settings: 2–5 mg subcutaneous or intramuscular injection, 1–3 times per week during a loading phase, transitioning to 2–5 mg every 2 weeks for maintenance. Duration: cycle-based use, typically 4–8 week loading cycles. Route: subcutaneous injection most common; intramuscular injection also described. These doses are empirically derived with no human dose-finding study basis.

About the LKKTETQ Fragment

The LKKTETQ fragment (the basis for commercial TB-500) was shown to be active in the Philp 2003 wound repair study in diabetic and aged mice — duplicating the parent molecule's effects in that model. This supports the rationale for using the synthetic truncated version. However, human pharmacokinetic data for the LKKTETQ fragment by systemic injection do not exist.

Safety & contraindications

Known, theoretical, and unknown risks.

Thymosin Beta-4 is naturally abundant in mammalian tissue, which provides some biological precedent for tolerance. However, no completed, peer-reviewed clinical safety trials for systemic TB-500 injection in humans exist. All safety characterization comes from preclinical data and topical corneal trials — which use a different route, concentration, and clinical context.

Preclinical Safety Signal

Animal studies have not identified major organ toxicity across multiple organ systems and doses. Tβ4's natural abundance in mammalian tissue — particularly in platelets and white blood cells — is consistent with a degree of biological precedent for tolerance. This is a favorable signal from animal data, not a human safety clearance.

Oncogenic Risk — Primary Theoretical Concern

Tβ4 stimulates angiogenesis and cell migration — properties shared with tumor growth biology. The primary safety concern, explicitly flagged by the 2025 Chornomydz systematic review, is "potential stimulation of undiagnosed tumors." Clinicians must explicitly evaluate cancer history and risk factors before initiating any TB-500 protocol. This concern applies to any pro-angiogenic peptide.

Compounding Quality Risks

As with BPC-157, TB-500 products from non-GMP sources carry contamination, endotoxin, and dosing accuracy risks. Injectable peptides require sterile preparation conditions (USP <797> compliance). Products sourced from unregulated "research chemical" suppliers do not meet these standards and carry substantial safety risk independent of the molecule's intrinsic profile.

Specific Population Contraindications

Pregnancy and nursing: contraindicated due to absent safety data. Active malignancy: explicit clinician and oncology consultation required; theoretical angiogenic risk is material. Pediatric patients: not established. Patients with history of fibrotic conditions: exercise clinical judgment — anti-fibrotic effects could theoretically disrupt normal healing scaffolding in some contexts.

Regulatory status — May 2026

Not approved, not on the bulks list, under review July 2026.

FDA Status and July 2026 PCAC Meeting

TB-500 / Thymosin Beta-4 is NOT FDA-approved for any systemic indication. RegeneRx's topical RGN-259 (Tβ4 eye drops) has completed Phase 2 trials for corneal healing but has not received FDA approval as of May 2026.

For 503A compounding: Thymosin Beta-4 / TB-500 is not on the FDA-approved 503A bulks list. It was not categorized as Category 2 (unlike BPC-157), but that reflects absence of formal evaluation rather than a safety determination. TB-500 is among the peptides under consideration at the FDA PCAC meeting on July 23–24, 2026. Per the FDA Drug Topics social media post (April 2026), the PCAC meeting will consider 7 peptides — including BPC-157 and TB-500 — for 503A listing.

Until the PCAC meeting outcome is known and FDA acts, TB-500 cannot be legally compounded under standard 503A frameworks. Operators should obtain real-time legal guidance and monitor FDA announcements.

WADA Prohibited — Athletes Must Not Use

TB-500 is prohibited by WADA under the Prohibited List for "Other Peptide Hormones and Related Substances." It was detected in equine doping control analysis as early as 2012 (Ho et al., J Chromatogr A). Athletes in sanctioned sports face real risk of anti-doping violations. This prohibition is current as of 2025 — unlike BPC-157, which is not currently on WADA's list.

Page update notice: This page will be updated following the July 23–24, 2026 FDA PCAC meeting with actual outcomes for TB-500/Thymosin Beta-4's 503A bulks list consideration. If the committee recommended inclusion, this page will be updated to reflect the resulting compounding pathway. If the committee recommended against, this page will note continued restriction.

FAQ

Common questions about TB-500 and Thymosin Beta-4.

What is the difference between Thymosin Beta-4 and TB-500?

Thymosin Beta-4 is the full 43-amino acid naturally occurring peptide found throughout mammalian tissue. TB-500 is a synthetic version of its active actin-binding domain — the LKKTETQ sequence (amino acids 17–23). Research suggests this fragment retains the parent molecule's key biological activities. Most commercial and clinical preparations labeled "TB-500" consist of this synthetic fragment.

Is there any human clinical trial data?

No peer-reviewed human RCTs for systemic TB-500 injection in musculoskeletal healing or recovery exist. Topical Tβ4 eye drops (RGN-259) have been evaluated in Phase 2 clinical trials for corneal healing — providing some human safety context for the peptide family but not validating systemic injection for sports injury or recovery applications.

Why do athletes report positive effects without trial data?

Anecdotal and self-reported experiences are common in the peptide community. The preclinical mechanisms are coherent. However, anecdotal reports cannot substitute for controlled trials — placebo effects, natural healing, and concurrent interventions are confounders that only randomized controlled trials can adequately account for. Self-reported improvement is not evidence of efficacy.

Can TB-500 cause cancer?

No preclinical evidence suggests Tβ4/TB-500 causes cancer. However, because the peptide promotes angiogenesis and cell migration — processes also central to tumor growth — theoretical concern exists that it could accelerate pre-existing undiagnosed tumors. Clinicians should evaluate cancer history and risk factors carefully before recommending any pro-angiogenic compound.

Is it banned in sports?

Yes. TB-500 is currently prohibited by WADA under "Other Peptide Hormones and Related Substances." Unlike BPC-157 (not currently prohibited), TB-500 remains on WADA's list. Athletes in sanctioned sports must not use TB-500. This is different from its FDA regulatory status — WADA prohibition and 503A compounding regulations are independent frameworks.

How does it compare to BPC-157?

Both are primarily supported by preclinical animal data with no systemic human RCTs. BPC-157 is more studied in musculoskeletal and GI models. Tβ4/TB-500 has broader literature including cardiac and corneal applications, with topical corneal use further into clinical trials. TB-500 is WADA-prohibited; BPC-157 is not. Both are under review at the July 2026 FDA PCAC meeting. No controlled combination data exist for protocols using both.

Informational only. Content on this page is for informational purposes and does not constitute medical advice. TB-500 / Thymosin Beta-4 is not FDA-approved for any systemic indication and is not on the FDA-approved 503A bulk drug substances list as of May 2026. TB-500 is prohibited by WADA for use by competitive athletes. All prescriptions are issued at the sole discretion of the prescribing clinician. This page will be updated following the July 23–24, 2026 FDA PCAC meeting. Last reviewed: May 2026.

Related

Continue exploring.

BPC-157

Also under review at the July 2026 FDA PCAC meeting. BPC-157 shares a preclinical evidence profile with TB-500 and is frequently explored in similar musculoskeletal and recovery contexts — though its mechanism, research history, and WADA status differ.

Read the BPC-157 Page

GH Secretagogues

CJC-1295, ipamorelin, tesamorelin — GHS compounds that work through the GH/IGF-1 axis. Tesamorelin has FDA approval and Level I evidence. Some recovery protocols combine GHS with TB-500 or BPC-157.

Explore GH Secretagogues

Start a Clinical Evaluation

A licensed clinician who is current on TB-500's regulatory status can evaluate your health history and discuss what options are legally and clinically appropriate for your situation.

Start Your Intake

Understand the science before you decide.

Preclinical evidence is compelling. Clinical translation remains unproven. Clinician evaluation bridges that gap.

Start your intake and connect with a licensed clinician who is current on TB-500's regulatory landscape and can evaluate whether any peptide protocol aligns with your clinical profile.

Start Your Intake Back to Peptide Library